Kashyap Patel
Kashyap Patel/kashyappatel.com

Kashyap Patel: Using the EpiSwitch CIRT Test to Assess the Likelihood of Response to Immunotherapy

Kashyap Patel, Past President at Community Oncology Alliance, shared a post on LinkedIn, about a recent article he and his colleagues co-authored, published in Cancers:

“Immunotherapy has significantly transformed the management of various solid tumors, including melanoma and other indications for cancer patients.

Despite its advancements, oncologists still lack a definitive positive predictive test to determine the best treatment option for each patient.

In collaboration with Oxford Biodynamics, we conducted a prospective, evidence-based study using the EpiSwitch CIRT test to assess the likelihood of response to immunotherapy.

We are thrilled to announce the publication of our findings in a peer-reviewed journal.”

Title: Clinical Utility of the EpiSwitch CiRT Test to Guide Immunotherapy Across Solid Tumors: Interim Results from the PROWES Study

Authors: Joe Abdo, Joos Berghausen, Ryan Mathis, Thomas Guiel, Ewan Hunter, Robert Heaton, Alexandre Akoulitchev, Sashi Naidu, Kashyap Patel

Read the Full Article on Cancers

Kashyap Patel: Using the EpiSwitch CIRT Test to Assess the Likelihood of Response to Immunotherapy

More posts featuring Kashyap Patel.